Pediatric high‐grade gliomas (pHGG) comprise a deadly, heterogenous category of
pediatric gliomas with a clear need for more effective treatment options. Advances in high …

Purpose Selinexor is a novel XPO1 inhibitor which inhibits the export of tumor suppressor
proteins and oncoprotein mRNAs, leading to cell-cycle arrest and apoptosis in cancer cells …

Cellular protein homeostasis (proteostasis) depends on the controlled degradation of
proteins that are damaged or no longer required by the ubiquitin-proteasome system (UPS) …

New drugs introduced to the market are privileged structures having affinities for biological
targets implicated in human diseases and conditions. These new chemical entities (NCEs) …

Chronic lymphocytic leukemia (CLL) is a subtype of B-cell malignancy with high
heterogeneity. XPO1 is highly expressed in many hematological malignancies, which …

Purpose: Selinexor is an oral selective inhibitor of exportin-1 (XPO1) with efficacy in various
solid and hematologic tumors. We assessed intratumoral penetration, safety, and efficacy of …

Across many cancer types in adults, upregulation of the nuclear-to-cytoplasmic transport
protein Exportin-1 (XPO1) correlates with poor outcome and responsiveness to selinexor, an …

An estimated 284,000 Americans will be diagnosed with breast cancer in 2021. Of these
individuals, 15–20% have basal-like triple-negative breast cancer (TNBC), which is known …

Simple Summary Glioblastoma multiforme (GBM) is the most aggressive primary brain
cancer; less than 50% of patients with GBM survive longer than 15 months. A biomarker for …

Protein localization is frequently manipulated to favor tumor initiation and progression. In
cancer cells, the nuclear export factor CRM1 is often overexpressed and aberrantly localizes …